clinical trial · NCT06607627
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc.·phase3·recruiting·n = 12
Generalized Myasthenia GravisgMGGefurulimab
brief summary
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
started
Nov 13, 2024
primary completion
Dec 15, 2026
completion
Jan 23, 2029
last updated
Apr 1, 2026
official title
An Open-Label, Single-arm Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, and Efficacy of Gefurulimab in Pediatric Patients (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG) Who Express Acetylcholine Receptor Antibodies (AChR+)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol